- Home
- TYGO vs TCRX Comparison
TYGO vs TCRX Comparison
Compare TYGO & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYGO
- TCRX
- Stock Information
- Founded
- TYGO 2007
- TCRX 2018
- Country
- TYGO United States
- TCRX United States
- Employees
- TYGO N/A
- TCRX N/A
- Industry
- TYGO Semiconductors
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- TYGO Technology
- TCRX Health Care
- Exchange
- TYGO Nasdaq
- TCRX Nasdaq
- Market Cap
- TYGO 82.5M
- TCRX 91.7M
- IPO Year
- TYGO N/A
- TCRX 2021
- Fundamental
- Price
- TYGO $1.71
- TCRX $1.84
- Analyst Decision
- TYGO Strong Buy
- TCRX Strong Buy
- Analyst Count
- TYGO 1
- TCRX 5
- Target Price
- TYGO $6.00
- TCRX $9.40
- AVG Volume (30 Days)
- TYGO 278.2K
- TCRX 210.5K
- Earning Date
- TYGO 11-05-2025
- TCRX 08-12-2025
- Dividend Yield
- TYGO N/A
- TCRX N/A
- EPS Growth
- TYGO N/A
- TCRX N/A
- EPS
- TYGO N/A
- TCRX N/A
- Revenue
- TYGO $74,405,000.00
- TCRX $6,961,000.00
- Revenue This Year
- TYGO $94.76
- TCRX $255.18
- Revenue Next Year
- TYGO $19.11
- TCRX N/A
- P/E Ratio
- TYGO N/A
- TCRX N/A
- Revenue Growth
- TYGO 52.31
- TCRX N/A
- 52 Week Low
- TYGO $0.58
- TCRX $1.02
- 52 Week High
- TYGO $1.80
- TCRX $6.23
- Technical
- Relative Strength Index (RSI)
- TYGO 77.23
- TCRX 52.96
- Support Level
- TYGO $1.34
- TCRX $1.73
- Resistance Level
- TYGO $1.45
- TCRX $1.96
- Average True Range (ATR)
- TYGO 0.10
- TCRX 0.12
- MACD
- TYGO 0.03
- TCRX 0.00
- Stochastic Oscillator
- TYGO 98.00
- TCRX 63.64
About TYGO Tigo Energy Inc.
Tigo Energy Inc designs solar power conversion and storage products that provide customers with more choice and flexibility. Its mission is to deliver smart hardware and software solutions that enhance safety, increase energy yield, and lower operating costs of residential, commercial, and utility-scale solar systems. Geographically the company generates revenue from EMEA, Americas, and APAC.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.